Thu, Oct 24, 2024
BSV, has developed recombinant and niche biologic products in-house, demonstrating its strong R&D capabilities and boasts of a robust branded product portfolio across women's health, fertility, critical care and immunoglobulins.
More >
Tue, Aug 27, 2024
Bharat Biotech International Ltd has launched Hillchol (BBV131), a novel single-strain oral cholera vaccine developed under license from Hilleman Laboratories.
Fri, Jul 26, 2024
The company has entered into a definitive agreement with Advent to acquire a 100 per cent stake in Bharat Serums and Vaccines (BSV) for an enterprise value of around Rs 13,630 crore, Mankind Pharma said in a statement.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
